Deutsche Bank Ag\ Infla Rx N.V. Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.47 - $3.51 $2,470 - $3,510	-1,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $261,070 - $4.4 Million	-85,317 Reduced 98.84%	1,000 $3,000
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $1.6 Million - $2.5 Million	51,317 Added 146.62%	86,317 $3.26 Million
Q4 2018 Feb 14, 2019	SELL	$23.33 - $36.37 $142,219 - $221,711	-6,096 Reduced 14.83%	35,000 $1.27 Million
Q3 2018 Nov 14, 2018	BUY	$29.34 - $35.0 $170,054 - $202,860	5,796 Added 16.42%	41,096 $1.41 Million

Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $8,199 - $12,438	300 Added 0.86%	35,300 $1.14 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $509,250 - $839,650	35,000	35,000 $733,000

13.8M

12.9K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $72.5M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.